Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have earned an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $61.00.

A number of analysts have recently issued reports on the company. Bank of America initiated coverage on Vera Therapeutics in a research report on Thursday, October 16th. They set a “buy” rating and a $48.00 price objective on the stock. Wolfe Research reissued a “peer perform” rating on shares of Vera Therapeutics in a report on Monday, August 4th. JPMorgan Chase & Co. reduced their price objective on shares of Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, November 7th. HC Wainwright lifted their target price on shares of Vera Therapeutics from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a research note on Thursday, September 18th.

Vera Therapeutics Stock Up 2.1%

NASDAQ VERA opened at $28.46 on Monday. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $51.27. The stock has a market cap of $1.82 billion, a PE ratio of -7.13 and a beta of 1.22. The firm has a 50-day simple moving average of $28.39 and a 200 day simple moving average of $24.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the previous year, the company posted ($0.85) earnings per share. On average, research analysts forecast that Vera Therapeutics will post -2.89 EPS for the current year.

Insider Buying and Selling at Vera Therapeutics

In other news, SVP Joseph R. Young sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the transaction, the senior vice president directly owned 47,839 shares of the company’s stock, valued at approximately $1,390,201.34. This represents a 23.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 16.30% of the company’s stock.

Institutional Trading of Vera Therapeutics

Large investors have recently bought and sold shares of the stock. Armistice Capital LLC raised its stake in Vera Therapeutics by 294.1% during the third quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock worth $15,576,000 after acquiring an additional 400,000 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Vera Therapeutics in the 3rd quarter worth about $1,188,000. Qube Research & Technologies Ltd increased its position in shares of Vera Therapeutics by 47.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 461,410 shares of the company’s stock worth $13,409,000 after purchasing an additional 149,468 shares in the last quarter. Prelude Capital Management LLC lifted its holdings in Vera Therapeutics by 81.8% during the 3rd quarter. Prelude Capital Management LLC now owns 46,551 shares of the company’s stock valued at $1,353,000 after purchasing an additional 20,951 shares during the last quarter. Finally, Millennium Management LLC boosted its position in Vera Therapeutics by 173.5% in the third quarter. Millennium Management LLC now owns 598,454 shares of the company’s stock valued at $17,391,000 after buying an additional 379,623 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.